Future Healthcare of America

Natur Holding B.V., the principle subsidiary of Natur International Corp, entered into a loan agreement with Dam! Holding B.V., under which Natur Holding could borrow up to US$560,915 or €500,000. The final terms of the agreement were concluded on February 18, 2019.The full drawdown of $560,915 was made in three tranches throughout January and February 2019. Repayment is due after six months from the date of receipt of the initial funds. The loan may be pre-paid in full or in part at any time. Interest, at the rate of 5% per annum, is due and payable quarterly. The loan carries a default interest rate of 11% per annum. There is a currently a translation difference of $20,320 due to foreign exchange rate differences. Following approval by the SEC in the third quarter of 2019 to increase the authorized share capital the company plans to fully convert this balance into equity, in the form of common stock, in the fourth quarter of 2019.

^{The Holder 6th} Wave Efficiency Life Fund agrees that if it sells any of the shares of Common Stock it was directly or beneficially issued by the Parent Company on November 13, 2018, either as shares of Common Stock or the Common Stock underlying the Class B Preferred Stock, in exchange for its equity interest in the Company and any of the Conversion Shares (together the Common Stock, the Common Stock underlying the Class B Preferred Stock and the Conversion Shares are referred to as the “Value Calculation Shares”) at any time prior to December 31, 2022, and the gross proceeds to the Holder or its affiliates from the sale (or deemed sale as provided herein) of any or all of the Value Calculation Shares exceeds USD $15,000,000, then the balance of the Debt, equal to USD $3,000,000 as of the date hereof and any interest, expenses, penalties, and other charges of any nature due thereon under the terms of the Debt Agreement (the “Debt Balance”), will be deemed fully paid, discharged and extinguished and the Debt Agreement in all respects will be terminated and of no further effect. There is a currently a translation difference of $15,7823 due to foreign exchange rate differences.

Following approval by the SEC in the third quarter of 2019 to increase the authorized share capital the company plans to fully convert this balance into equity, in the form of common stock, in the fourth quarter of 2019.

As part of the sale, Temple issued warrants, exercisable for the greater of 1,493,735 shares of common stock of Temple or 2.5% of the equity of the Temple on a fully diluted basis. The exercise price per share is the par value of the common stock of Temple to be acquired upon exercise of the Warrant. The exercise period is ten years, but not later than the earlier of the consummation of the initial public offering by Temple or a sale transaction of Temple, as defined in the Warrant. The Warrant has a limited cashless conversion right and has typical anti-dilution rights for dividends, reverse splits and changes in the capitalization of Temple.  As of the date of this filing, it is understood that the holder of the issued warrants is in the process of filing for bankruptcy. Due to the current negative outlook for the business of the holder and the limited transfer rights of the warrant to a third party in the event of bankruptcy of the holder, the company has deemed the fair value of the warrant at this point in time to be $nil. The company will continue to monitor the situation on a regular basis and will adjust the value of the warrant based on the then actual situation.

Based on the business plan, the Company acquired a majority stake in Temple, a functional beverage company in the USA in July 2019. It entered into a binding LOI in August 2019 to acquire a majority stake of Infinite, a USA-based CBD company. With SIH, a Dutch-based company with its main activities in China, a binding LOI was agreed in June 2019 to acquire SIH based on a share exchange, and the definitive share exchange agreement with SIH was signed October 26, 2019 and closing of the transaction is expected before the end of this fiscal year. During September 2019, the Company established an online sales platform in Bulgaria to service the Eastern European markets. Discussions with potential private investors are still on-going.

On October 29, 2019, we reached a tentative agreement with claimant to resolve her claims of sexual harassment.   The terms of this settlement are that Interim will pay to Lori Norby and her counsel, the total sum of $10,000 in exchange for a full release by Ms. Norby of Interim Healthcare of Wyoming, and claims asserted against John Busshaus, and Crystal Burback-Morse will be dismissed with prejudice.  A Notice of Settlement has been signed by Plaintiff’s counsel and filed with the Court, however we are still awaiting receipt of the final Settlement Agreement from the Plaintiff.   

On October 18, 2019, we entered into an Agreement with the Equal Employment Opportunity Commission (“EEOC”) to resolve the claims that Interim committed gender discrimination in paying male employees a higher wage than female employees.  The terms of that Agreement are that Interim agreed to entry of a judgment against it.  The terms of that Judgment include that Interim will pay the sum of $25,000 allocated to 5 previous female employees which make up the claimant group, as compensatory damages, plus an additional $25,000, and the employer portion of federal payroll taxes on those amounts, to these 5 previous employees as back wages.  Interim also agreed to a list of training and supervision requirements, but those requirements only become applicable if Interim Healthcare of Wyoming, Inc., operates “any healthcare or homecare-related business” in the US in the next 4 years.  We are currently working on issuing the payments described above to the previous employees, and should have that completed within the next 7-10 days.  In exchange for these payments, Interim is receiving the EEOC’s complete release of all claims for unlawful employment practices under Title VII and the Equal Pay Act that arise from the Charge of Discrimination filed by Nicole Aaker in Charge No. 541-2016-01546.